Logo image of ALMDP.PA

Medesis Pharma SA (ALMDP.PA) Stock Overview

Europe - EPA:ALMDP - FR0010844464 - Common Stock

0.35 EUR
-0.03 (-8.14%)
Last: 3/10/2025, 7:00:00 PM

ALMDP.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.77M
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares5.06M
Float4.21M
52 Week High2.4
52 Week Low0.3
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2021-02-12
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A


ALMDP.PA short term performance overview.The bars show the price performance of ALMDP.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

ALMDP.PA long term performance overview.The bars show the price performance of ALMDP.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALMDP.PA is 0.35 EUR. In the past month the price decreased by -10.71%. In the past year, price decreased by -76.67%.

Medesis Pharma SA / ALMDP Daily stock chart

About ALMDP.PA

Company Profile

ALMDP logo image Medesis Pharma SA operates as a clinical development stage biopharmaceutical company, which engages in the research and development of orally administered molecule drugs. The company is headquartered in Baillargues, Occitanie. The company went IPO on 2021-02-12. The firm is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.

Company Info

Medesis Pharma SA

L'Oree des Mas Avenue du Golf, Montpellier

Baillargues OCCITANIE FR

Employees: 10

ALMDP Company Website

ALMDP Investor Relations

Phone: 33467030396

Medesis Pharma SA / ALMDP.PA FAQ

Can you describe the business of Medesis Pharma SA?

Medesis Pharma SA operates as a clinical development stage biopharmaceutical company, which engages in the research and development of orally administered molecule drugs. The company is headquartered in Baillargues, Occitanie. The company went IPO on 2021-02-12. The firm is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.


Can you provide the latest stock price for Medesis Pharma SA?

The current stock price of ALMDP.PA is 0.35 EUR. The price decreased by -8.14% in the last trading session.


Does Medesis Pharma SA pay dividends?

ALMDP.PA does not pay a dividend.


What is the ChartMill technical and fundamental rating of ALMDP stock?

ALMDP.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


How is the market expecting ALMDP stock to perform?

7 analysts have analysed ALMDP.PA and the average price target is 0.82 EUR. This implies a price increase of 133.14% is expected in the next year compared to the current price of 0.35.


ALMDP.PA Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ALMDP.PA. When comparing the yearly performance of all stocks, ALMDP.PA is a bad performer in the overall market: 97.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALMDP.PA Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

ALMDP.PA Forecast & Estimates

7 analysts have analysed ALMDP.PA and the average price target is 0.82 EUR. This implies a price increase of 133.14% is expected in the next year compared to the current price of 0.35.


Analysts
Analysts40
Price Target0.82 (134.29%)
EPS Next YN/A
Revenue Next YearN/A

ALMDP.PA Ownership

Ownership
Inst OwnersN/A
Ins Owners11.57%
Short Float %N/A
Short RatioN/A